Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase II randomized placebo-controlled, single-blind, multi-center dose-escalation study to evaluate tolerability, safety, pharmacokinetics, and pharmacodynamics of a single intravenous administration of INO-1001 in subjects with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention: Results of the TIMI 37A trial

DA Morrow, K Baran, R Krakover, H Dauerman, SA Murphy, S Kumar, CH McCabe, CM Brickman, AL Salzman. A phase II randomized placebo-controlled, single-blind, multi-center dose-escalation study to evaluate tolerability, safety, pharmacokinetics, and pharmacodynamics of a single intravenous administration of INO-1001 in subjects with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention: Results of the TIMI 37A trial. J Am Coll Cardiol. 2007; 49(9):202A.


© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.